problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201561343-46problendo-7721Research ArticleСтатьиArticlesНовые иммунологические методы диагностики аутоиммунного полиэндокринного синдрома 1-го типаThe new immunological methods for diagnostics of type 1 autoimmune polyendocrine syndromeСозаеваЛ СSozaevaL Sleila.sozaeva@gmail.comФГБУ «Эндокринологический научный центр»Endocrinology Research Centre201515062015613ТОМ 61, №3 (2015)4346Copyright © Созаева Л.С., 20152015Созаева Л.С.Sozaeva L.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/7721

Аутоиммунный полигландулярный синдром 1-го типа (АПС 1-го типа) - редкое генетическое заболевание, причиной которого являются мутации в гене AIRE. Наряду с генетическими исследованиями для диагностики заболевания возможно исследование уровня антител к интерферонам 1-го типа, в частности к интерферонам-ω и -α2. Приведен обзор литературы, касающейся интерферонов 1-го типа, антител к ним и патофизиологии процессов, индуцируемых антителами к интерферонам.

Type 1 autoimmune polyglandular syndrome (type 1APS) is a rare genetic disease resulting from mutations in the AIRE gene. Diagnostics of this pathology is based not only on the results of genetic studies but also on the measurement of the level of antibodies against type 1 interferons, such as interferon-ω and interferon-α2. The present review of the literature is focused on type 1 interferons, anti-interferon antibodies, and pathophysiological characteristics of the processes induced by these antibodies.

аутоиммунный полигланулярный синдром 1-го типатимомаалопецияинтерфероны-ωинтерфероны-α2радиоиммунный анализметод HEK-blue cellsautoimmune polyglandular syndromethymomaalopeciainterferon-ωinterferon-α2radioimmunoassayHEK-Blue cell techniqueReferencesJääskeläinen J, Perheentupa J. Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (apeced)--a diagnostic and therapeutic challenge. Pediatr Endocrinol Rev. 2009;7(2):95-108.Jääskeläinen J, Perheentupa J. Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (apeced)--a diagnostic and therapeutic challenge. Pediatr Endocrinol Rev. 2009;7(2):95-108.Ahonen P. Autoimmune polyendocrinopathy - candidosis - ectodermal dystrophy (apeced): autosomal recessive inheritance. Clin Genet. 2008;27(6):535-542. doi: 10.1111/j.1399-0004.1985.tb02037.x.Ahonen P. Autoimmune polyendocrinopathy - candidosis - ectodermal dystrophy (apeced): autosomal recessive inheritance. Clin Genet. 2008;27(6):535-542. doi: 10.1111/j.1399-0004.1985.tb02037.x.Anderson MS. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395-1401. doi: 10.1126/science.1075958.Anderson MS. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395-1401. doi: 10.1126/science.1075958.Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006;24(1):571-606. doi: 10.1146/annurev.immunol.23.021704.115601.Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol. 2006;24(1):571-606. doi: 10.1146/annurev.immunol.23.021704.115601.Орлова ЕМ. Генетические основы и клинические варианты аутоиммунного полигландулярного синдрома ١-го типа: Дис. … канд. мед. наук. М.; 2005. [Orlova EM. Geneticheskie osnovy i klinicheskie varianty autoimmunnogo poliglandulyarnogo sindroma 1 tipa [PhD dissertation]. Moscow; 2005. (In Russ.)].Орлова ЕМ. Генетические основы и клинические варианты аутоиммунного полигландулярного синдрома ١-го типа: Дис. … канд. мед. наук. М.; 2005. [Orlova EM. Geneticheskie osnovy i klinicheskie varianty autoimmunnogo poliglandulyarnogo sindroma 1 tipa [PhD dissertation]. Moscow; 2005. (In Russ.)].Orlova EM, Bukina AM, Kuznetsova ES, еt al. Autoimmune polyglandular syndrome type I in russian patients: clinical variants and autoimmune regulator mutations. Horm Res Paediatr. 2010;73(6):449-457. doi: 10.1159/000313585.Orlova EM, Bukina AM, Kuznetsova ES, еt al. Autoimmune polyglandular syndrome type I in russian patients: clinical variants and autoimmune regulator mutations. Horm Res Paediatr. 2010;73(6):449-457. doi: 10.1159/000313585.Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type I. Plos Med. 2006;3(7):e289. doi: 10.1371/journal.pmed.0030289.Meager A, Visvalingam K, Peterson P, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type I. Plos Med. 2006;3(7):e289. doi: 10.1371/journal.pmed.0030289.Vilcek J. Novel interferons. Nat Immunol. 2003;4(1):8-9. doi: 10.1038/ni0103-8.Vilcek J. Novel interferons. Nat Immunol. 2003;4(1):8-9. doi: 10.1038/ni0103-8.Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202(1):8-32. doi: 10.1111/j.0105-2896.2004.00204.x.Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202(1):8-32. doi: 10.1111/j.0105-2896.2004.00204.x.Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132(1):128-136. doi: 10.1046/j.1365-2249.2003.02113.x.Meager A, Wadhwa M, Dilger P, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132(1):128-136. doi: 10.1046/j.1365-2249.2003.02113.x.Kisand K, Link M, Wolff ASB, et al. Interferon autoantibodies associated with aire deficiency decrease the expression of ifn-stimulated genes. Blood. 2008;112(7):2657-2666. doi: 10.1182/blood-2008-03-144634.Kisand K, Link M, Wolff ASB, et al. Interferon autoantibodies associated with aire deficiency decrease the expression of ifn-stimulated genes. Blood. 2008;112(7):2657-2666. doi: 10.1182/blood-2008-03-144634.Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type i interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008;93(11):4389-4397. doi: 10.1210/jc.2008-0935.Meloni A, Furcas M, Cetani F, et al. Autoantibodies against type i interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2008;93(11):4389-4397. doi: 10.1210/jc.2008-0935.Oftedal BE, Bøe Wolff AS, Bratland E, et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol. 2008;129(1):163-169. doi: 10.1016/j.clim.2008.07.002.Oftedal BE, Bøe Wolff AS, Bratland E, et al. Radioimmunoassay for autoantibodies against interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin Immunol. 2008;129(1):163-169. doi: 10.1016/j.clim.2008.07.002.Wolff ASB, Sarkadi AK, Maródi L, et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol. 2013;33(8):1341-1348. doi: 10.1007/s10875-013-9938-6.Wolff ASB, Sarkadi AK, Maródi L, et al. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol. 2013;33(8):1341-1348. doi: 10.1007/s10875-013-9938-6.Breivik L, Oftedal BEV, Bøe Wolff AS, et al. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type I. Clin Immunol. 2014;153(1):220-227. doi: 10.1016/j.clim.2014.04.013.Breivik L, Oftedal BEV, Bøe Wolff AS, et al. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type I. Clin Immunol. 2014;153(1):220-227. doi: 10.1016/j.clim.2014.04.013.

The authors declare that there are no conflicts of interest present.